Equillium Inc Sustainability Reports
Equillium, Inc. is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics. The company primarily targets severe autoimmune and inflammatory disorders with high unmet medical needs.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300OC7SSPSNNGHE64
FIGI: BBG00LSL8C29
3 reports from 2018 to 2024
